Sacubitril/valsartan
(Source: Reactions Weekly)
Source: Reactions Weekly - March 1, 2024 Category: Drugs & Pharmacology Source Type: research
Effect of sacubitril/valsartan on lipid metabolism in patients with chronic kidney disease combined with chronic heart failure: a retrospective study
Dyslipidemia is significantly more common in those with concurrent chronic kidney disease (CKD) and chronic heart failure (CHF). Sacubitril/valsartan has showcased its influence on both cardiac and renal funct... (Source: Lipids in Health and Disease)
Source: Lipids in Health and Disease - February 28, 2024 Category: Lipidology Authors: Manzhi Li, Ao Zhong, Yifan Tang, Jinnuo Yu, Mengmeng Wu, Karthick Kumaran Munisamy Selvam and Dong Sun Tags: Research Source Type: research
Clinical implications of subclinical left ventricular dysfunction in heart failure with preserved ejection fraction: The PARAGON ‐HF study
ConclusionsIn a large HFpEF population, impaired LV function was observed even among patients with preserved ejection fraction, and was associated with an increased risk of total HF hospitalizations or cardiovascular death, accounting for clinical confounders. These findings highlight the key role of subtle LV systolic impairment in the pathophysiology of HFpEF. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - February 19, 2024 Category: Cardiology Authors: Masatoshi Minamisawa,
Riccardo M. Inciardi,
Brian Claggett,
Maja Cikes,
Li Liu,
Narayana Prasad,
Tor Biering ‐Sørensen,
Carolyn S.P. Lam,
Sanjiv J. Shah,
Michael R. Zile,
Eileen O'Meara,
Margaret M. Redfield,
John J.V. McMurray,
Scott D. S Tags: Research Article Source Type: research
Rationale and protocol of the LAQUA-HF trial: a factorial randomised controlled trial evaluating the effects of neurohormonal and diuretic agents on health-status reported outcomes in heart failure patients
Introduction
The current guidelines strongly recommend early initiation of multiple classes of cardioprotective drugs for patients with heart failure with reduced ejection fraction to improve prognosis and health status. However, evidence on the optimal sequencing of approved drugs is scarce, highlighting the importance of individualised treatment plans. Registry data indicate that only a portion of these patients can tolerate all four recommended classes, underscoring the need to establish the favoured sequence when using these drugs. Additionally, the choice between long-acting and short-acting loop diuretics in the pres...
Source: BMJ Open - February 14, 2024 Category: General Medicine Authors: Shiraishi, Y., Ikemura, N., Urashima, M., Kohno, T., Nakano, S., Tanaka, T., Nagatomo, Y., Ikoma, T., Ono, T., Numasawa, Y., Sakamoto, M., Nishikawa, K., Takei, M., Hakuno, D., Nakamaru, R., Ueda, I., Kohsaka, S. Tags: Open access, Medical management Source Type: research
Sacubitril/valsartan inhibits the proliferation of vascular smooth muscle cells through notch signaling and ERK1/2 pathway
To explore the role and mechanism of Notch signaling and ERK1/2 pathway in the inhibitory effect of sacubitril/valsartan on the proliferation of vascular smooth muscle cells (VSMCs). (Source: BMC Cardiovascular Disorders)
Source: BMC Cardiovascular Disorders - February 14, 2024 Category: Cardiology Authors: Congfeng Xu, Ning Zhang, Hong Yuan, Liren Wang and Yonghong Li Tags: Research Source Type: research
Sacubitril/valsartan ameliorates tubulointerstitial fibrosis by restoring mitochondrial homeostasis in diabetic kidney disease
Tubulointerstitial fibrosis plays an important role in the progression of diabetic kidney disease (DKD). Sacubitril/valsartan (Sac/Val) exerts a robust beneficial effect in DKD. However, the potential function... (Source: Diabetology and Metabolic Syndrome)
Source: Diabetology and Metabolic Syndrome - February 10, 2024 Category: Endocrinology Authors: Xing-Jian Zhang, Cong-Cong Liu, Zuo-Lin Li, Lin Ding, Yan Zhou, Dong-Jie Zhang, Yao Zhang, Shu-Ting Hou and Rui-Xia Ma Tags: Research Source Type: research
A Comparative Analysis of the Clinical Efficacy of Sacubitril Valsartan Sodium and Enalapril in Patients with Non-Valvular Ejection Fraction Reduction in Heart Failure
CONCLUSION: The main findings of the study showed that Sacubitril valsartan sodium showed better clinical efficacy than enalapril in patients with heart failure and non-valvular reduced ejection fraction. Specifically, the drug significantly improved patients' kidney function, reduced cardiovascular marker levels, and reduced the incidence of adverse cardiovascular events. These findings have important clinical implications for guiding treatment selection in patients with heart failure.PMID:38330576 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - February 8, 2024 Category: Complementary Medicine Authors: Qinqqing Zhang Jiao Wang Yingxiao Da Xin Li Lei Pan Source Type: research
A Comparative Analysis of the Clinical Efficacy of Sacubitril Valsartan Sodium and Enalapril in Patients with Non-Valvular Ejection Fraction Reduction in Heart Failure
CONCLUSION: The main findings of the study showed that Sacubitril valsartan sodium showed better clinical efficacy than enalapril in patients with heart failure and non-valvular reduced ejection fraction. Specifically, the drug significantly improved patients' kidney function, reduced cardiovascular marker levels, and reduced the incidence of adverse cardiovascular events. These findings have important clinical implications for guiding treatment selection in patients with heart failure.PMID:38330576 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - February 8, 2024 Category: Complementary Medicine Authors: Qinqqing Zhang Jiao Wang Yingxiao Da Xin Li Lei Pan Source Type: research
A Comparative Analysis of the Clinical Efficacy of Sacubitril Valsartan Sodium and Enalapril in Patients with Non-Valvular Ejection Fraction Reduction in Heart Failure
CONCLUSION: The main findings of the study showed that Sacubitril valsartan sodium showed better clinical efficacy than enalapril in patients with heart failure and non-valvular reduced ejection fraction. Specifically, the drug significantly improved patients' kidney function, reduced cardiovascular marker levels, and reduced the incidence of adverse cardiovascular events. These findings have important clinical implications for guiding treatment selection in patients with heart failure.PMID:38330576 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - February 8, 2024 Category: Complementary Medicine Authors: Qinqqing Zhang Jiao Wang Yingxiao Da Xin Li Lei Pan Source Type: research
A Comparative Analysis of the Clinical Efficacy of Sacubitril Valsartan Sodium and Enalapril in Patients with Non-Valvular Ejection Fraction Reduction in Heart Failure
CONCLUSION: The main findings of the study showed that Sacubitril valsartan sodium showed better clinical efficacy than enalapril in patients with heart failure and non-valvular reduced ejection fraction. Specifically, the drug significantly improved patients' kidney function, reduced cardiovascular marker levels, and reduced the incidence of adverse cardiovascular events. These findings have important clinical implications for guiding treatment selection in patients with heart failure.PMID:38330576 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - February 8, 2024 Category: Complementary Medicine Authors: Qinqqing Zhang Jiao Wang Yingxiao Da Xin Li Lei Pan Source Type: research
A Comparative Analysis of the Clinical Efficacy of Sacubitril Valsartan Sodium and Enalapril in Patients with Non-Valvular Ejection Fraction Reduction in Heart Failure
CONCLUSION: The main findings of the study showed that Sacubitril valsartan sodium showed better clinical efficacy than enalapril in patients with heart failure and non-valvular reduced ejection fraction. Specifically, the drug significantly improved patients' kidney function, reduced cardiovascular marker levels, and reduced the incidence of adverse cardiovascular events. These findings have important clinical implications for guiding treatment selection in patients with heart failure.PMID:38330576 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - February 8, 2024 Category: Complementary Medicine Authors: Qinqqing Zhang Jiao Wang Yingxiao Da Xin Li Lei Pan Source Type: research
A Comparative Analysis of the Clinical Efficacy of Sacubitril Valsartan Sodium and Enalapril in Patients with Non-Valvular Ejection Fraction Reduction in Heart Failure
CONCLUSION: The main findings of the study showed that Sacubitril valsartan sodium showed better clinical efficacy than enalapril in patients with heart failure and non-valvular reduced ejection fraction. Specifically, the drug significantly improved patients' kidney function, reduced cardiovascular marker levels, and reduced the incidence of adverse cardiovascular events. These findings have important clinical implications for guiding treatment selection in patients with heart failure.PMID:38330576 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - February 8, 2024 Category: Complementary Medicine Authors: Qinqqing Zhang Jiao Wang Yingxiao Da Xin Li Lei Pan Source Type: research
Nitrosamines, ICH Q3A-Q3E, Global Substance Registration System (GSRS), N-nitroso dimethyl amine (NDMA), Drug substance life cycle
Curr Top Med Chem. 2024 Feb 6. doi: 10.2174/0115680266278636240125113509. Online ahead of print.ABSTRACTSince their discovery in valsartan-containing drugs, nitrosamine impurities have emerged as a significant safety problem in pharmaceutical products, prompting extensive recalls and suspensions. Valsartan, candesartan, irbesartan, olmesartan, and other sartans have been discovered to have additional nitrosamine impurities, such as N-nitroso-N-methyl-4-aminobutyric acid (NMBA), N-nitroso-Di-isopropyl amine (NDIPA), N-nitroso-Ethyl-Isopropyl amine (NEIPA), and N-nitroso-Diethyl amine (NDEA). Concerns about drug safety have ...
Source: Current Topics in Medicinal Chemistry - February 7, 2024 Category: Chemistry Authors: Darshan Bhirud Gyan Agrawal Harshil Shah Artiben Patel Mahesh B Palkar Sankha Bhattacharya Bhupendra G Prajapati Source Type: research
Management of Fluoropyrimidine-Induced Cardiac Adverse Outcomes Following Cancer Treatment
Cardiovasc Toxicol. 2024 Feb 7. doi: 10.1007/s12012-024-09834-9. Online ahead of print.ABSTRACTAdvancements in cancer treatments have improved survival rates but have also led to increased cardiotoxicities, which can cause adverse cardiovascular events or worsen pre-existing conditions. Herein, cardiotoxicity is a severe adverse effect of 5-fluorouracil (5-FU) therapy in cancer patients, with reported incidence rates ranging from 1 to 20%. Some studies have also suggested subclinical effects and there are reports which have documented instances of cardiac arrest or sudden death during 5-FU treatment, highlighting the impor...
Source: Cardiovascular Toxicology - February 7, 2024 Category: Cardiology Authors: Mohsen Rajaeinejad Peyvand Parhizkar-Roudsari Mehran Khoshfetrat Mohammad Hassan Kazemi-Galougahi Reza Mosaed Rasta Arjmand Seyed Abolfazl Mohsenizadeh Babak Arjmand Source Type: research
